The object of this investigation was to evaluate the use of aureomycin in obstetric patients. Since the advent of the sulfonamide drugs and penicillin investigators have continued to search for new antibiotics which would be effective and less toxic. One of the products of this search, aureomycin, was discovered by Duggar in 1948.1 Extensive bacteriologic and clinical studies have established the effectiveness of this agent in a wide variety of infections. Its mode of action, as determined in vitro, is predominately bacteriostatic, but it also possesses bactericidal properties at high concentration. Because of the promising results reported with aureomycin, including its use in obstetric complications,2 a study of this drug and its effect on the bacteriologic flora and infections during pregnancy and the puerperium was believed warranted.
MATERIAL AND METHODS
Aureomycin was prescribed according to various dosage schedules as noted under the individual descriptions. The in vitro studies
GUILBEAU JA, SCHOENBACH EB, SCHAUB IG, LATHAM DV. AUREOMYCIN IN OBSTETRICS: THERAPY AND PROPHYLAXIS. JAMA. 1950;143(6):520-526. doi:10.1001/jama.1950.02910410006002